TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04937036

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography
Study: NCT05642676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinics remodeling
Description: changes to the clinics will be planned based on baseline surveys
Study: NCT05567458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06178796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Dental implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Dental implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Dental implant placement
Study: NCT05368038

Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmatory Testing
Description: All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
Study: NCT05502939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Program
Description: The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After School Enrichment Program
Description: The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
Study: NCT06423950

Intervention type: OTHER
Intervention: Peds Evolutionary Tumor Board (pedsETB)
Description: The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.
Study: NCT05407389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-301 (formerly US-APR2020)
Description: KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
Study: NCT06578364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Educational Program about Preconception Care
Description: The educational program consisted of a single session, which included a lecture, pictures, videos, and discussions.
Study: NCT04003285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
Study: NCT04590664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV
Study: NCT04677647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OurChild mHealth Digital Platform
Description: The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
Study: NCT06105060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
Study: NCT06494020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Practice combined with Transcutaneous Spinal Cord Stimulation( TcSCS)
Description: Hand rehabilitative tasks ( for gross hand movement, grasp and pinch tasks) will be done by participants during which time the participant will receive TcSCS. This will be done three times a week for 60 minutes.
Study: NCT05302089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management and shoulder bandage
Description: All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain management and shoulder bandage
Description: All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-time physiotherapy instruction
Description: Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-time physiotherapy instruction
Description: Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation care
Description: At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
Study: NCT04830137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-2127
Description: Oral NX-2127
Study: NCT05466422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2214
Description: MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as an IV infusion on Days 1, 29, and 57
Study: NCT04773951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Description: Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
Study: NCT05696236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL) monitor and stopping rules
Description: The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitor (TEWL) without stopping rules
Description: The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
Study: NCT05678608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical excision
Description: posterior midline approach and total excision for spinal cord tumors
Study: NCT06137326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field Therapy
Description: Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Acupuncture
Description: Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
Study: NCT06331559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 Tablets
Description: Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 Tablets
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 in combination with olaparib
Description: Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0501 in combination with olaparib
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
Study: NCT05597202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 2.0 mg/mL
Description: Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
Study: NCT05620667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immature ponkan (Citrus reticulate) extract
Description: Drink 25mL for once, and once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immature ponkan (Citrus reticulate) extract
Description: Drink 25mL for once, and once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drink 25mL for once, and once a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time restricted feeding
Description: Controlling a shortened period of time for eating within 8 hour each day.
Study: NCT06298929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial rectus fenestration
Description: Fenestration technique involves making two splitting incisions by blunt dissection parallel to the muscle fibers on the superior and inferior borders of the muscle, leaving 1 mm of muscle fibers on each edge. The rectangular wide central part is excised from the insertion and between the two splitting incisions to a point back 5-8 mm depending on the angle of the esotropia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial rectus recession
Description: recession is one of the gold standard weakening procedures that involves disinsertion of the muscle and re-suturing to the sclera at a more posterior location to decrease its contractile power.
Study: NCT05609110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
Study: NCT05075265

Intervention type: DRUG
Intervention: Methadone
Description: Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
Study: NCT05764525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study: NCT06420960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearing the connected watch
Description: All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address.~They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing the connected watch
Description: All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address.~They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance.
Study: NCT06446817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxHighAdd IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LuxGood IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study: NCT05041413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moms Quit
Description: Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text4Baby
Description: Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
Study: NCT05362656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VX1+ dispersion mapping
Description: Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
Study: NCT04609956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality consists of a headphones, a virtual reality headset and a smartphone.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Description: Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
Study: NCT04983017

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement
Description: iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo to Intervention
Study: NCT05876078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doraya catheter
Description: Temporary deployment of the Doraya catheter in ADHF patients
Study: NCT04950127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Participants will receive linerixibat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Participants will receive linerixibat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Participants will receive linerixibat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo.
Study: NCT05537883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
Study: NCT05655351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-Cov-2 vaccination
Description: For the purposes of the study, 10 mL of venous blood will be collected from each patient.
Study: NCT05590377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab SC injection
Study: NCT04789603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-min-walk surgical mask
Description: To walk as fast as possible without running for 6 minutes with surgical mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-min-walk Fpp2
Description: To walk as fast as possible without running for 6 minutes with Fpp2 mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-min-walk without mask
Description: To walk as fast as possible without running for 6 minutes without mask
Study: NCT06253988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: intra-pocket formula (local delivery drug)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo formula
Description: intra-pocket formula (local delivery drug)